PMID- 37546243
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230808
IS  - 1178-7074 (Print)
IS  - 1178-7074 (Electronic)
IS  - 1178-7074 (Linking)
VI  - 16
DP  - 2023
TI  - Metabolic Profile and Negatively Association Between Insulin Resistance and 
      Metastatic Incidence in Indonesian Primary Invasive Breast Cancer: A 
      Cross-Sectional Study.
PG  - 3257-3265
LID - 10.2147/IJGM.S421558 [doi]
AB  - INTRODUCTION: Metastatic breast cancer was associated with high morbidity and 
      mortality. Insulin resistance was hypothesized to be related to the incidence of 
      advanced breast cancer. Homeostatic Model Assessment of Insulin Resistance 
      (HOMA-IR) and Triglyceride/Glucose Index (TyG Index) are two metrics used to 
      measure the degree of insulin resistance. This study aims to assess the 
      relationship between the incidence of metastatic breast cancer and insulin 
      resistance as reflected by both metrics. MATERIAL AND METHODS: This study is a 
      cross-sectional study involving 150 primary invasive breast cancer patients 
      recruited from two hospitals of different sectors from August 2019 to April 2020. 
      Patients with double cancer and autoimmune disorder were excluded from this 
      study. Data obtained from the patients include age, body mass index (BMI), type 2 
      diabetes mellitus (T2DM) status and treatment, and low-density lipoprotein (LDL) 
      cholesterol. The electronic medical records (EMR) was consulted to find 
      histopathology examination result, cancer staging, and any missing data. The 
      association between HOMA-IR and TyG with metastatic incidence was analyzed using 
      either the Mann-Whitney test (for non-normally distributed data) or the 
      independent-sample t-test (for normally distributed data). RESULTS: The mean of 
      the TyG index is 8.60, and the median of HOMA-IR is 1.22. We found no significant 
      correlation between both variables and the incidence of metastases. CONCLUSION: 
      Insulin resistance was not associated with metastatic breast cancer.
CI  - (c) 2023 Rachman et al.
FAU - Rachman, Andhika
AU  - Rachman A
AUID- ORCID: 0000-0003-3246-3352
AD  - Division of Hematology and Medical Oncology, Department of Internal Medicine, 
      Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, 
      Jakarta, Indonesia.
AD  - Siloam MRCCC Semanggi Hospital, Jakarta, Indonesia.
FAU - Fiantoro, Zaenal Hakiki
AU  - Fiantoro ZH
AD  - Departement of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Dr. 
      Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
FAU - Sutandyo, Noorwati
AU  - Sutandyo N
AD  - Dharmais National Cancer Referral Hospital, Jakarta, Indonesia.
FAU - Priantono, Dimas
AU  - Priantono D
AUID- ORCID: 0000-0003-0348-7902
AD  - Division of Hematology and Medical Oncology, Department of Internal Medicine, 
      Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, 
      Jakarta, Indonesia.
FAU - Romadhon, Pradana Zaky
AU  - Romadhon PZ
AUID- ORCID: 0000-0001-9306-5425
AD  - Division of Hematology and Medical Oncology, Department of Internal Medicine, 
      Airlangga University, Surabaya, Indonesia.
FAU - Jonlean, Reganedgary
AU  - Jonlean R
AD  - Tzu Chi Hospital, Jakarta, Indonesia.
LA  - eng
PT  - Journal Article
DEP - 20230801
PL  - New Zealand
TA  - Int J Gen Med
JT  - International journal of general medicine
JID - 101515487
PMC - PMC10404037
OTO - NOTNLM
OT  - HOMA-IR
OT  - TyG index
OT  - breast cancer
OT  - metastases
COIS- The authors declared no conflicts of interest in this work.
EDAT- 2023/08/07 06:41
MHDA- 2023/08/07 06:42
PMCR- 2023/08/01
CRDT- 2023/08/07 04:34
PHST- 2023/05/25 00:00 [received]
PHST- 2023/07/21 00:00 [accepted]
PHST- 2023/08/07 06:42 [medline]
PHST- 2023/08/07 06:41 [pubmed]
PHST- 2023/08/07 04:34 [entrez]
PHST- 2023/08/01 00:00 [pmc-release]
AID - 421558 [pii]
AID - 10.2147/IJGM.S421558 [doi]
PST - epublish
SO  - Int J Gen Med. 2023 Aug 1;16:3257-3265. doi: 10.2147/IJGM.S421558. eCollection 
      2023.